These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 29032033)
1. Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrier. Perrone MG; Vitale P; Ferorelli S; Boccarelli A; Coluccia M; Pannunzio A; Campanella F; Di Mauro G; Bonaccorso C; Fortuna CG; Scilimati A Eur J Med Chem; 2017 Dec; 141():404-416. PubMed ID: 29032033 [TBL] [Abstract][Full Text] [Related]
2. An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acid. Perrone MG; Miciaccia M; Vitale P; Ferorelli S; Araújo CDCB; de Almeida GS; Souza Domingos TF; da Silva LCRP; de Pádula M; Cabral LM; Sathler PC; Bonaccorso C; Fortuna CG; Scilimati A Eur J Med Chem; 2021 Jan; 209():112919. PubMed ID: 33129592 [TBL] [Abstract][Full Text] [Related]
3. Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection. Scilimati A; Ferorelli S; Iaselli MC; Miciaccia M; Pati ML; Fortuna CG; Aleem AM; Marnett LJ; Perrone MG Eur J Med Chem; 2019 Oct; 179():16-25. PubMed ID: 31229884 [TBL] [Abstract][Full Text] [Related]
4. Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability. Pati ML; Vitale P; Ferorelli S; Iaselli M; Miciaccia M; Boccarelli A; Di Mauro GD; Fortuna CG; Souza Domingos TF; Rodrigues Pereira da Silva LC; de Pádula M; Cabral LM; Sathler PC; Vacca A; Scilimati A; Perrone MG Eur J Med Chem; 2019 Feb; 164():59-76. PubMed ID: 30590258 [TBL] [Abstract][Full Text] [Related]
5. A further pocket or conformational plasticity by mapping COX-1 catalytic site through modified-mofezolac structure-inhibitory activity relationships and their antiplatelet behavior. Solidoro R; Miciaccia M; Bonaccorso C; Fortuna CG; Armenise D; Centonze A; Ferorelli S; Vitale P; Rodrigues P; Guimarães R; de Oliveira A; da Paz M; Rangel L; Sathler PC; Altomare A; Perrone MG; Scilimati A Eur J Med Chem; 2024 Feb; 266():116135. PubMed ID: 38219659 [TBL] [Abstract][Full Text] [Related]
6. Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6). Cingolani G; Panella A; Perrone MG; Vitale P; Di Mauro G; Fortuna CG; Armen RS; Ferorelli S; Smith WL; Scilimati A Eur J Med Chem; 2017 Sep; 138():661-668. PubMed ID: 28710965 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile. Abdelazeem AH; El-Saadi MT; Safi El-Din AG; Omar HA; El-Moghazy SM Bioorg Med Chem; 2017 Jan; 25(2):665-676. PubMed ID: 27916468 [TBL] [Abstract][Full Text] [Related]
8. General role of the amino and methylsulfamoyl groups in selective cyclooxygenase(COX)-1 inhibition by 1,4-diaryl-1,2,3-triazoles and validation of a predictive pharmacometric PLS model. Perrone MG; Vitale P; Panella A; Fortuna CG; Scilimati A Eur J Med Chem; 2015 Apr; 94():252-64. PubMed ID: 25768707 [TBL] [Abstract][Full Text] [Related]